Implandata announces closing of €3m funding round
27 October 2014
Hannover-based Implandata Ophthalmic Products GmbH has announced
the closing of a €3m Series B funding round that included Born2Grow
Venture Partners as new investor.
Previous investors, all German companies, Peppermint Charité
Beteiligungsfonds, Hannover Beteiligungsfonds, High-Tech
Gründerfonds, KfW and a group of business angels completed the
Series B funding round.
The funding enables the company to complete the clinical program
for CE marking of its first product, to launch further studies for
complementary product lines and applications in Germany and abroad,
specifically to initiate the first IDE study with Massachusetts Eye
and Ear Infirmary, Boston/MA and Kellogg Eye Institute, Ann Arbor/MI.
For this purpose and in order to prepare the commercial launch of
Implandata’s products in the USA, the company established a fully
owned US subsidiary Implandata Ophthalmic Products, Inc., located in
The company plans to start further clinical studies for expansion
of product use, for clinical validation of complementary product
versions and for integrating its pressure sensing technology
platform into other ophthalmic surgical procedures and products.
Implandata is currently conducting the multi-centric ARGOS-02
study with its intraocular pressure sensor for continuous monitoring
of glaucoma patients' eye pressure. During cataract surgery
Implandata’s pressure sensing implant is placed in front of the
artificial intraocular lens, posterior to the iris.
After implantation of the micro sensor the patient’s intraocular
pressure can be measured at any chosen frequency, either
continuously over the course of 24 hours or on demand at defined
time points. Patients can perform measurements by themselves and
under normal live conditions. Collected data will be sent via a
mobile phone module to the eye doctor’s computer screen, allowing
remotely monitoring and managing the patient’s disease and alerting
the eye doctor in case of patients uncontrolled intraocular
Implandata’s intraocular pressure sensor allows close monitoring
of the patients disease progression and glaucoma therapy success.
Through simple and more frequent measurements of intraocular
pressure - which is the key parameter in glaucoma therapy -
important information on therapy response is delivered to the eye
doctor early on, enabling immediate glaucoma therapy adjustment,
contributing to prevention of further vision loss due to
uncontrolled intraocular pressure.
Source: Implandata Ophthalmic Products GmbH